Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 15065 | 7.81 |
09:34 ET | 6183 | 7.9799 |
09:36 ET | 8094 | 7.9591 |
09:38 ET | 6486 | 7.98 |
09:39 ET | 6970 | 7.96 |
09:41 ET | 2567 | 7.95 |
09:43 ET | 2319 | 7.93 |
09:45 ET | 8925 | 7.8601 |
09:48 ET | 3192 | 7.84 |
09:50 ET | 8768 | 7.79 |
09:52 ET | 3341 | 7.85 |
09:54 ET | 1624 | 7.85 |
09:57 ET | 200 | 7.81 |
09:59 ET | 5700 | 7.8 |
10:01 ET | 3277 | 7.7601 |
10:03 ET | 1931 | 7.79 |
10:06 ET | 2375 | 7.8 |
10:08 ET | 6040 | 7.83 |
10:10 ET | 988 | 7.83 |
10:12 ET | 4031 | 7.8 |
10:14 ET | 1146 | 7.8 |
10:15 ET | 949 | 7.84 |
10:17 ET | 4849 | 7.8 |
10:19 ET | 1944 | 7.85 |
10:21 ET | 2300 | 7.83 |
10:24 ET | 5108 | 7.79 |
10:26 ET | 2500 | 7.79 |
10:28 ET | 7461 | 7.77 |
10:30 ET | 5330 | 7.76 |
10:32 ET | 6305 | 7.785 |
10:33 ET | 2850 | 7.75 |
10:35 ET | 2800 | 7.755 |
10:37 ET | 14603 | 7.77 |
10:39 ET | 3300 | 7.81 |
10:42 ET | 2768 | 7.79 |
10:44 ET | 6141 | 7.75 |
10:46 ET | 768 | 7.79 |
10:48 ET | 1111 | 7.79 |
10:50 ET | 11977 | 7.78 |
10:51 ET | 700 | 7.78 |
10:53 ET | 100 | 7.77 |
10:55 ET | 6000 | 7.76 |
10:57 ET | 8111 | 7.73 |
11:00 ET | 1499 | 7.745 |
11:02 ET | 15162 | 7.76 |
11:04 ET | 4900 | 7.73 |
11:06 ET | 2320 | 7.735 |
11:08 ET | 7836 | 7.71 |
11:09 ET | 44098 | 7.745 |
11:11 ET | 11112 | 7.73 |
11:13 ET | 600 | 7.73 |
11:15 ET | 1800 | 7.72 |
11:18 ET | 1600 | 7.7 |
11:20 ET | 16663 | 7.705 |
11:22 ET | 744 | 7.71 |
11:24 ET | 2249 | 7.72 |
11:26 ET | 5689 | 7.68 |
11:27 ET | 6545 | 7.68 |
11:29 ET | 400 | 7.69 |
11:31 ET | 4026 | 7.7 |
11:33 ET | 2971 | 7.67 |
11:36 ET | 12993 | 7.6831 |
11:38 ET | 1650 | 7.67 |
11:40 ET | 23423 | 7.66 |
11:42 ET | 6038 | 7.6987 |
11:44 ET | 3780 | 7.68 |
11:45 ET | 1900 | 7.695 |
11:47 ET | 3774 | 7.69 |
11:49 ET | 4006 | 7.68 |
11:51 ET | 1200 | 7.68 |
11:54 ET | 3197 | 7.69 |
11:56 ET | 200 | 7.7 |
11:58 ET | 2191 | 7.71 |
12:00 ET | 433 | 7.71 |
12:02 ET | 7053 | 7.75 |
12:03 ET | 300 | 7.745 |
12:05 ET | 331 | 7.74 |
12:07 ET | 400 | 7.73 |
12:09 ET | 200 | 7.735 |
12:12 ET | 2225 | 7.7301 |
12:14 ET | 2000 | 7.7335 |
12:16 ET | 3699 | 7.71 |
12:18 ET | 2610 | 7.69 |
12:20 ET | 494 | 7.69 |
12:21 ET | 4668 | 7.71 |
12:23 ET | 2188 | 7.71 |
12:25 ET | 2680 | 7.73 |
12:27 ET | 550 | 7.75 |
12:30 ET | 1337 | 7.73 |
12:32 ET | 600 | 7.74 |
12:34 ET | 6921 | 7.7001 |
12:36 ET | 9349 | 7.7 |
12:38 ET | 1000 | 7.71 |
12:39 ET | 3505 | 7.7099 |
12:41 ET | 4221 | 7.69 |
12:43 ET | 1700 | 7.69 |
12:45 ET | 1950 | 7.7199 |
12:48 ET | 1663 | 7.71 |
12:50 ET | 12044 | 7.72 |
12:52 ET | 300 | 7.725 |
12:54 ET | 200 | 7.725 |
12:56 ET | 928 | 7.71 |
12:57 ET | 6787 | 7.74 |
12:59 ET | 690 | 7.739 |
01:01 ET | 3645 | 7.755 |
01:03 ET | 2774 | 7.78 |
01:06 ET | 300 | 7.78 |
01:08 ET | 1115 | 7.78 |
01:10 ET | 300 | 7.77 |
01:12 ET | 1726 | 7.78 |
01:14 ET | 200 | 7.78 |
01:15 ET | 2391 | 7.77 |
01:17 ET | 2595 | 7.78 |
01:19 ET | 202 | 7.78 |
01:21 ET | 2328 | 7.76 |
01:24 ET | 2100 | 7.77 |
01:26 ET | 1600 | 7.75 |
01:28 ET | 26473 | 7.79 |
01:30 ET | 3523 | 7.79 |
01:32 ET | 6700 | 7.78 |
01:33 ET | 1807 | 7.74 |
01:35 ET | 4485 | 7.74 |
01:37 ET | 54060 | 7.71 |
01:39 ET | 3428 | 7.74 |
01:42 ET | 2451 | 7.76 |
01:44 ET | 800 | 7.75 |
01:46 ET | 3391 | 7.775 |
01:48 ET | 3482 | 7.78 |
01:50 ET | 3118 | 7.74 |
01:51 ET | 3600 | 7.74 |
01:53 ET | 1363 | 7.74 |
01:55 ET | 4016 | 7.7 |
01:57 ET | 2311 | 7.72 |
02:00 ET | 6027 | 7.71 |
02:02 ET | 1850 | 7.71 |
02:04 ET | 23980 | 7.7277 |
02:06 ET | 3720 | 7.72 |
02:08 ET | 3940 | 7.73 |
02:09 ET | 3400 | 7.72 |
02:11 ET | 4100 | 7.73 |
02:13 ET | 4690 | 7.76 |
02:15 ET | 1967 | 7.7499 |
02:18 ET | 4112 | 7.76 |
02:20 ET | 1871 | 7.77 |
02:22 ET | 1145 | 7.75 |
02:24 ET | 9823 | 7.76 |
02:26 ET | 986 | 7.755 |
02:27 ET | 2426 | 7.755 |
02:29 ET | 1935 | 7.75 |
02:31 ET | 1046 | 7.75 |
02:33 ET | 7250 | 7.76 |
02:36 ET | 500 | 7.75 |
02:38 ET | 28956 | 7.79 |
02:40 ET | 3482 | 7.77 |
02:42 ET | 4010 | 7.79 |
02:44 ET | 2408 | 7.8 |
02:45 ET | 2509 | 7.82 |
02:47 ET | 3935 | 7.795 |
02:49 ET | 12952 | 7.79 |
02:51 ET | 6582 | 7.7778 |
02:54 ET | 6175 | 7.78 |
02:56 ET | 3786 | 7.75 |
02:58 ET | 2744 | 7.75 |
03:00 ET | 3623 | 7.76 |
03:02 ET | 1799 | 7.76 |
03:03 ET | 2300 | 7.75 |
03:05 ET | 6770 | 7.76 |
03:07 ET | 6854 | 7.78 |
03:09 ET | 2900 | 7.78 |
03:12 ET | 2024 | 7.77 |
03:14 ET | 864 | 7.76 |
03:16 ET | 15566 | 7.76 |
03:18 ET | 5584 | 7.76 |
03:20 ET | 4104 | 7.74 |
03:21 ET | 801 | 7.75 |
03:23 ET | 1849 | 7.74 |
03:25 ET | 1640 | 7.74 |
03:27 ET | 11416 | 7.77 |
03:30 ET | 1400 | 7.765 |
03:32 ET | 5080 | 7.76 |
03:34 ET | 9828 | 7.75 |
03:36 ET | 829 | 7.75 |
03:38 ET | 5508 | 7.75 |
03:39 ET | 9841 | 7.75 |
03:41 ET | 2498 | 7.75 |
03:43 ET | 2200 | 7.75 |
03:45 ET | 13231 | 7.751 |
03:48 ET | 6241 | 7.765 |
03:50 ET | 14621 | 7.755 |
03:52 ET | 12563 | 7.79 |
03:54 ET | 33136 | 7.81 |
03:56 ET | 69158 | 7.84 |
03:57 ET | 57979 | 7.8 |
03:59 ET | 2616105 | 7.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.5B | -47.1x | --- |
Viking Therapeutics Inc | 5.8B | -57.0x | --- |
Madrigal Pharmaceuticals Inc | 6.0B | -12.1x | --- |
Krystal Biotech Inc | 5.2B | 97.6x | --- |
Nuvalent Inc | 4.9B | -31.5x | --- |
BridgeBio Pharma Inc | 4.7B | -7.8x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.5B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.98 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -47.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.